New Treatment Challenges for EGFR-Mutant Lung Cancer!

• July 4, 2025
• Read time: 1 minute

[Treatment Challenges in EGFR-Mutant Non-Small Cell Lung Cancer] Detection of EGFR gene mutations and targeted therapy have greatly improved outcomes for non-small cell lung cancer patients. However, these patients are more prone to brain metastases — especially those unresponsive to EGFR tyrosine kinase inhibitors (EGFR-TKI) — becoming a major clinical challenge.

Key Data:

• Among EGFR-mutant patients, the incidence of brain metastases is significantly higher than other cancer types.
• Patients unresponsive to EGFR-TKI have a further 50% increased risk of brain metastasis.
• Effective treatment regimens are being continuously explored to improve patient quality of life.

More details: https://tinyurl.com/26x4trtw

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4